期刊文献+

MTM模式下心脏瓣膜置换术后患者服用华法林的抗凝治疗效果评价 被引量:3

Evaluation of anticoagulant treatment effect of warfarin in patients after heart valve replacement in MTM mode
在线阅读 下载PDF
导出
摘要 目的评估药物治疗管理(medication therapy management,MTM)服务模式下心脏瓣膜置换术后患者服用华法林的抗凝治疗效果,包括药物治疗效果和药师服务效果。方法对新疆医科大学第一附属医院2022年12月-2023年4月行心脏瓣膜置换术的门诊及住院患者,有明确的纳入、排除标准并服用华法林进行抗凝治疗的两组患者,研究组是药师参与下MTM药学服务模式组,对照组是常规医疗服务模式组,比较两组患者在行心脏瓣膜置换术后使用华法林进行抗凝治疗的效果差异。结果MTM药学服务模式下患者华法林抗凝质量(TTR)达标率(58.95%)是常规医疗服务模式组患者TTR达标率(34.49%)的1.71倍;MTM模式下患者对华法林的认知度和用药依从性较好。结论MTM药学服务模式比常规医疗服务模式下患者的治疗效果更佳,药师在针对患者的个体化治疗中起着更加重要的作用,也为进一步推进MTM药师服务模式提供数据支持。 Objective To evaluate of medication therapy management(MTM)pharmacists service mode after heart valve replacement patients taking warfarin anticoagulant treatment effect,including drug therapy and medicine service effect.Methods From December 2022 to April 2023,the outpatient and inpatient patients who underwent heart valve replacement in the first affiliated hospital of Xinjiang medical university were divided into two groups with clear inclusion and exclusion criteria and taking warfarin for anticoagulant therapy.The research group was the MTMpharmaceutical care model group with the participation of pharmacists,and the control group was the routine medical service model group.The effect of warfarin anticoagulant therapy after heart valve replacement was compared between the two groups.Results The compliance rate of warfarin anticoagulant quality(TTR)in patients under the MTMpharmacist service mode(58.95%)was 1.71 times that of patients in the routine medical service mode group(34.49%),patients under the MTM mode had better awareness and medication compliance with warfarin.Conclusion MTMpharmaceutical care mode than routine medical services to patients with better treatment effects,the pharmacist plays a more important role for individualized treatment in the patients,which also provide data support for further advance MTMpharmacists service mode.
作者 向云霞 蒲文 李明清 李东锋 XIANG Yunxia;PU Wen;LI Mingqing;LI Dongfeng(Department of Pharmacy,the First Affiliated Hospital of Xinjiang Medical University,Urumqi,830054,China;Clinical Pharmacy,Department of Pharmacy,Xinjiang Medical University,Urumqi,830054,China)
出处 《新疆医学》 2023年第11期1304-1307,1343,共5页 Xinjiang Medical Journal
基金 2019年新疆维吾尔自治区药学会科研基金(项目编号:YXH201916)。
关键词 心脏瓣膜置换术 药物治疗管理 华法林 Heart valve replacement Medication therapeutical management Warfarin
作者简介 向云霞,女,硕士,主管药师,研究方向:临床药学与医院药学;通信作者:李东锋,男,主任药师,研究方向:临床药学,E-mail:ldf3438net@126.com。
  • 相关文献

参考文献14

二级参考文献141

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量:1406
  • 2胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:163
  • 3Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652.
  • 4Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146:S57-867.
  • 5Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coil Cardiol, 2008, 52: 865-868.
  • 6Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293.
  • 7Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719.
  • 8Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :eddS- 88S.
  • 9Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :e152S-184S.
  • 10Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics, 2010, 11 : 493 -496.

共引文献875

同被引文献37

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部